1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo. 2. Lecanemab also resulted in moderately less decline in cognitive and functional measures at 18-month follow-up as compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Rates of Alzheimer’s disease are increasing annually, introducing a considerable burden to